Could an experimental imaging tracer detect inflammation in neurodegenerative diseases?

The Cleveland Clinic Lou Ruvo Center for Brain Health (OH, USA) has obtained the only Investigational New Drug to be issued by the Federal Drug Administration to test the GE180 ligand tracer, an experimental diagnostic imaging tool used to detect neuroinflammation, in the brains of people with Parkinson’s and Alzheimer’s disease.

Researchers hope to better understand the link between inflammation and neurodegeneration, as well determine if the tracer works in a new application: a patient population consisting of people with normal cognitive function, and individuals with Alzheimer’s and Parkinson’s disease. At present, the Lou Ruvo Center for Brain Health is the first and only trial site testing the ligand tracer in this cohort.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.